ALLK News and Press, Allakos Inc. From 03/30/21

REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptan...

Allakos has a molecule targeting a largely undiagnosed market. If their prevalence study is any good, the potential for the therapy is huge. The company has strong cash balance and major catalysts in 12 months. For further details see: Allakos: Prevalence Data Shows A La...

Allakos (ALLK): Q4 GAAP EPS of -$0.86 in-line.Cash, cash equivalents and marketable securities of $659MPress Release For further details see: Allakos Q4 EPS in-line

REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter...

Cantor Fitzgerald has initiated the coverage of Allakos ([[ALLK]] +2.7%) with an overweight rating. The analyst Emma Nealon highlights the value of the company’s lead product candidate lirentelimab in eosinophil-driven inflammatory diseases.The price target at $218.00 per share implies...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive offic...

Allakos (ALLK): Q3 GAAP EPS of -$0.86 misses by $0.02.Cash, cash equivalents and marketable securities of $419.8M.Press Release For further details see: Allakos EPS misses by $0.02

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter e...

REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroentero...